Determinants of protective humoral response to mRNA-1273 and BNT162b2 vaccines in peritoneal dialysis patients: a prospective cohort study.
Humans
BNT162 Vaccine
/ immunology
Male
Female
Peritoneal Dialysis
Middle Aged
Prospective Studies
COVID-19
/ prevention & control
2019-nCoV Vaccine mRNA-1273
/ immunology
Aged
Antibodies, Viral
/ blood
Immunity, Humoral
SARS-CoV-2
/ immunology
COVID-19 Vaccines
/ immunology
Renal Insufficiency, Chronic
/ immunology
Adult
Cohort Studies
Chronic kidney disease
Covid19 mRNA vaccines
Peritoneal dialysis
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
07
07
2023
accepted:
30
09
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Patients with chronic kidney disease (CKD) on dialysis have a higher mortality rate associated with SARS-CoV-2 infection. Although vaccines are now available, the protective response rates and determinants of humoral response to the vaccine are poorly described in patients on peritoneal dialysis. This was a prospective observational study describing the response rates of detectable and standardized protective antibody titers one month after each mRNA vaccine dose in a cohort of 88 patients on peritoneal dialysis. We found that the vast majority of patients produced protective levels of antibodies (73%) one month after the second vaccine dose. In the multivariate analysis, the single determinant for an adequate humoral response was the weekly Kt/V, a surrogate of dialysis dose. The response rate was higher, but not significantly, with the mRNA-1273 than with the BNT162b2 vaccine one month after the second dose (78.7 vs. 46.2%, respectively, p = 0.02). We found that patients on peritoneal dialysis had a satisfactory humoral response rate, which was much higher than in transplant recipients. PD patients with a poor humoral response, particularly those with a low wKT/V, may benefit from an additional dose of vaccine.
Identifiants
pubmed: 39482652
doi: 10.1186/s12882-024-03789-3
pii: 10.1186/s12882-024-03789-3
doi:
Substances chimiques
BNT162 Vaccine
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
Antibodies, Viral
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
391Informations de copyright
© 2024. The Author(s).
Références
COVID-19 situation update for the EU/EEA. as of 24 June 2021. European Centre for Disease Prevention and Control. [cited 2021 Jun 24]. https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea
Scarpioni R, Manini A, Valsania T, De Amicis S, Albertazzi V, Melfa L et al. Covid-19 and its impact on nephropathic patients: the experience at Ospedale Guglielmo Da Saliceto in Piacenza. G Ital Nefrol Organo Uff Della Soc Ital Nefrol. 2020;37(2).
Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. Kidney Int. 2020;98(1):20–6.
doi: 10.1016/j.kint.2020.04.030
pubmed: 32437768
pmcid: 7206428
Goicoechea M, Sánchez Cámara LA, Macías N, Muñoz de Morales A, Rojas ÁG, Bascuñana A, et al. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain. Kidney Int. 2020;98(1):27–34.
doi: 10.1016/j.kint.2020.04.031
pubmed: 32437770
pmcid: 7211728
Valeri AM, Robbins-Juarez SY, Stevens JS, Ahn W, Rao MK, Radhakrishnan J, et al. Presentation and outcomes of patients with ESKD and COVID-19. J Am Soc Nephrol JASN. 2020;31(7):1409–15.
doi: 10.1681/ASN.2020040470
pubmed: 32467113
Dimitrov Y, Ducher M, Kribs M, Laurent G, Richter S, Fauvel JP. Variables linked to hepatitis B vaccination success in non-dialyzed chronic kidney disease patients: Use of a bayesian model. Nephrol Ther. 2019;15(4):215–9.
doi: 10.1016/j.nephro.2019.02.010
pubmed: 31129001
Soni R, Horowitz B, Unruh M. Immunization in end-stage renal disease: opportunity to improve outcomes. Semin Dial. 2013;26(4):416–26.
doi: 10.1111/sdi.12101
pubmed: 23751048
Raskova J, Ghobrial I, Czerwinski DK, Shea SM, Eisinger RP, Raska K. B-cell activation and immunoregulation in end-stage renal disease patients receiving hemodialysis. Arch Intern Med. 1987;147(1):89–93.
doi: 10.1001/archinte.1987.00370010091022
pubmed: 3492183
Anand S, Montez-Rath ME, Han J, Garcia P, Cadden L, Hunsader P, et al. Antibody response to COVID-19 vaccination in patients receiving Dialysis. J Am Soc Nephrol JASN. 2021;32(10):2435–8.
doi: 10.1681/ASN.2021050611
pubmed: 34117129
Garcia P, Anand S, Han J, Montez-Rath M, Sun S, Shang T et al. COVID19 vaccine type and humoral immune response in patients receiving dialysis. MedRxiv Prepr Serv Health Sci. 2021;2021.08.02.21261516.
Hsu CM, Weiner DE, Aweh GN, Manley HJ, Ladik V, Frament J, et al. Seroresponse to SARS-CoV-2 vaccines among maintenance Dialysis patients. Am J Kidney Dis 2022;79(2):307–10.
doi: 10.1053/j.ajkd.2021.10.002
Dimitrov Y, Krummel T, Chantrel F, Faller AL, Ott J, David D, et al. Protective antibody response to mRNA-1273 and BNT162b2 vaccines in patients on maintenance haemodialysis: a prospective cohort study. Clin Kidney J. 2022;15(9):1720–6.
doi: 10.1093/ckj/sfac082
pubmed: 35999964
pmcid: 9383598
Frantzen L, Cavaillé G, Thibeaut S, El-Haik Y. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a haemodialysis cohort. Nephrol Dial Transplant off Publ Eur Dial Transpl Assoc -. Eur Ren Assoc. 2021;36(9):1756–7.
Lacson E, Argyropoulos CP, Manley HJ, Aweh G, Chin AI, Salman LH, et al. Immunogenicity of SARS-CoV-2 vaccine in Dialysis. J Am Soc Nephrol JASN. 2021;32(11):2735–42.
doi: 10.1681/ASN.2021040432
pubmed: 34348908
Rodríguez-Espinosa D, Broseta JJ, Maduell F, Bedini JL, Vera M. Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients. Kidney Int. 2021;100(2):476–7.
doi: 10.1016/j.kint.2021.05.018
pubmed: 34081947
pmcid: 8166036
Beilhack G, Monteforte R, Frommlet F, Gaggl M, Strassl R, Vychytil A. Antibody response and safety after mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis patients - the Vienna Cohort. Front Immunol. 2021;12:780594.
doi: 10.3389/fimmu.2021.780594
pubmed: 34925359
pmcid: 8674530
Haase M, Lesny P, Haase-Fielitz A, Anderson M, Cloherty G, Stec M, et al. Immunogenicity and tolerability of COVID-19 vaccination in peritoneal dialysis patients-A prospective observational cohort study. Semin Dial. 2022;35(3):269–77.
doi: 10.1111/sdi.13043
pubmed: 34854131
Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032–40.
doi: 10.1038/s41591-021-01540-1
pubmed: 34588689
pmcid: 8604724
Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, et al. Anti-spike protein assays to Determine SARS-CoV-2 antibody levels: a Head-to-Head comparison of five quantitative assays. Microbiol Spectr. 2021;9(1):e0024721.
doi: 10.1128/Spectrum.00247-21
pubmed: 34190591
Yanay NB, Freiman S, Shapira M, Wishahi S, Hamze M, Elhaj M et al. Experience with SARS-COV-2 BNT162b2 mRNA vaccine in dialysis patients. Kidney Int. 2021. 99(6):1496-1498
Agur T, Ben-Dor N, Goldman S, Lichtenberg S, Herman-Edelstein M, Yahav D, et al. Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients - a prospectivecohort study. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc; 2021.
Longlune N, Nogier MB, Miedougé M, Gabilan C, Cartou C, Seigneuric B, et al. High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant 2021; 36(9):1704-1709
Tylicki L, Piotrowska M, Biedunkiewicz B, Zieliński M, Dąbrowska M, Tylicki P et al. Humoral response to COVID–19 vaccination in patients treated with peritoneal dialysis: the COViNEPH Project. Pol Arch Intern Med. 2021;131(10):16091
Boongird S, Chuengsaman P, Phanprasert S, Kitpermkiat R, Assanatham M, Nongnuch A, et al. Anti-SARS-CoV-2 spike protein S1 receptor-binding domain antibody after vaccination with inactivated whole-virus SARS-CoV-2 in end-stage kidney disease patients: an initial report. Kidney Int. 2021;100(5):1136–8.
doi: 10.1016/j.kint.2021.08.007
pubmed: 34419552
pmcid: 8375247
Murt A, Altiparmak MR, Ozbey D, Yalin SF, Sert Yadigar S, Karaali R, et al. Antibody responses to inactivated SARS-CoV-2 vaccine in peritoneal dialysis patients. Semin Dial. 2022;35(3):264–8.
doi: 10.1111/sdi.13049
pubmed: 34989454
Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, et al. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol CJASN. 2021;16(7):1037–42.
doi: 10.2215/CJN.03500321
pubmed: 33824157
Espi M, Charmetant X, Barba T, Koppe L, Pelletier C, Kalbacher E, et al. The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. Kidney Int. 2021;100(4):928–36.
doi: 10.1016/j.kint.2021.07.005
pubmed: 34284044
pmcid: 8286235
Danthu C, Hantz S, Dahlem A, Duval M, Ba B, Guibbert M, et al. Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of Hemodialysis patients and kidney transplant recipients. J Am Soc Nephrol JASN. 2021;32(9):2153–8.
doi: 10.1681/ASN.2021040490
pubmed: 34135083
Svác J, Skladaný L, Sekerková Z, Javorský P, Leskova L, Mizla P, et al. Peritoneal dialysis is the better therapy choice for successful anti-hepatitis B vaccination. Adv Perit Dial Conf Perit Dial. 2005;21:151–3.
Dervisoglu E, Simsek M, Yilmaz A. Antibody response following Hepatitis B vaccination in peritoneal dialysis patients: does normalized urea clearance matter? Clinics. 2011;66(9):1559–62.
doi: 10.1590/S1807-59322011000900009
pubmed: 22179159
pmcid: 3164404
Dacko C, Holley JL. The influence of nutritional status, dialysis adequacy, and residual renal function on the response to hepatitis B vaccination in peritoneal dialysis patients. Adv Perit Dial Conf Perit Dial. 1996;12:315–7.
Quiroga B, Soler MJ, Ortiz A, Bernat A, Muñoz Díaz AB, Jarava Mantecón CJ, et al. Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study. Nephrol Dial Transplant 2022;37(5):994–9.
Monzó JJB, Rodríguez-Espinosa D, Soruco E, Maduell F. Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in hemodialysis patients. Nephrol Dial Transplant 2021;36(9):1754-1755